Chlamydia and Gonorrhea Test Available for Wider Use

binx health io CT/NG is an easy to use test for chlamydia and gonorrhea that gives reliable results in about 30 minutes

If your email program has trouble displaying this email, view as a webpage. FDA Grants CLIA Waiver to Allow First Point-of-Care Chlamydia and Gonorrhea Test To Be Used More Widely   Today, the U.S. Food and Drug Administration (FDA) announced that a point-of-care test for chlamydia and gonorrhea may now be used in more health care settings including physician offices, community-based clinics, urgent care settings, outpatient health care facilities and other patient care settings operating under a CLIA Certificate of Waiver. The binx health io CT/NG Assay: Gives results comparable to a laboratory-based test for chlamydia and gonorrhea in about 30 minutes rather than days or weeks. Allows health care providers to provide diagnosis, a treatment plan, and counseling in a single patient visit. Makes it easier for patients to get quicker test results and appropriate treatment. This action is the result of the FDA granting a waiver under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") for the binx health io CT/NG Assay. Learn More Questions? If you have questions about the new CLIA waived test, contact the Division of Industry and Consumer Education.

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA